EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacology of Senolytics for Lung Aging and COPD: An Emerging Therapeutic Frontier

Sarah Gadavala F, Sheetal Buddhadev, Sandip Buddhadev

Global Journal of Medical and Clinical Case Reports · 23.02.2026 · 13 (2) · 026-031

DOI: 10.17352/gjmccr.000241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global Journal of Medical and Clinical Case Reports, online erschienen am 23.02.2026. Verfasst von Sarah Gadavala F und 2 weiteren Autor:innen. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic obstructive pulmonary disease is strongly influenced by accelerated lung aging and an accumulation of senescent cells within airway epithelial and immune compartments. Senescent cells release a spectrum of inflammatory mediators that worsen tissue destruction and impair repair mechanisms. Conventional COPD therapeutics do not adequately address cellular senescence, which has led to growing interest in senolytic drugs that selectively eliminate senescent cells or reduce harmful secretory signaling. Several senolytic candidates, including Dasatinib–Quercetin, Fisetin, Navitoclax, HSP90 inhibitors, and peptide-based approaches, have demonstrated promising effects in preclinical respiratory models. These agents modulate pathways such as BCL-2 inhibition, suppression of PI3K/AKT signaling, activation of mitochondrial apoptosis, or disruption of FOXO4–p53 interactions. Early studies suggest potential for reducing chronic inflammation, restoring epithelial function, and slowing structural deterioration in the lung. Although human evidence remains limited and concerns surrounding toxicity, delivery, and biomarker development persist, senolytics represent an emerging pharmacological avenue for targeting lung aging and may hold therapeutic value in COPD.

Zitieren

APA

F, S. G., Buddhadev, S., & Buddhadev, S. (2026). Pharmacology of Senolytics for Lung Aging and COPD: An Emerging Therapeutic Frontier. Global Journal of Medical and Clinical Case Reports, 13(2), 026-031. https://doi.org/10.17352/gjmccr.000241

Vancouver

F SG, Buddhadev S, Buddhadev S. Pharmacology of Senolytics for Lung Aging and COPD: An Emerging Therapeutic Frontier. Global Journal of Medical and Clinical Case Reports. 2026;13(2):026-031. doi:10.17352/gjmccr.000241

BibTeX
@article{F2026,
  author = {F, Sarah Gadavala and Buddhadev, Sheetal and Buddhadev, Sandip},
  title = {Pharmacology of Senolytics for Lung Aging and COPD: An Emerging Therapeutic Frontier},
  journal = {Global Journal of Medical and Clinical Case Reports},
  year = {2026},
  volume = {13},
  number = {2},
  pages = {026--031},
  doi = {10.17352/gjmccr.000241}
}
Kostenlos starten →